Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.
HS Code Reference
Personal Projective Equipment
For Reference Standard and R&D, Not for Human Use Directly.
provides coniferyl ferulate(CAS#:82358-44-9) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate
In patients with metastatic castrate‐resistant prostate cancer (mCRPC), circulating tumor DNA (ctDNA) analysis offers novel opportunities for the development of non‐invasive biomarkers informative of treatment response with novel agents targeting the androgen‐receptor (AR) pathway, such as abiraterone or enzalutamide. However, the relationship between ctDNA abundance, detectable somatic genomic alterations and clinical progression of mCRPC remains unexplored. Our study aimed to investigate changes in plasma DNA during disease progression and their associations with clinical variables in mCRPC patients. We analyzed ctDNA in two cohorts including 94 plasma samples from 25 treatment courses (23 patients) and 334 plasma samples from 125 patients, respectively. We conducted whole‐genome sequencing (plasma‐Seq) for genome‐wide profiling of somatic copy number alterations and targeted sequencing of 31 prostate cancer‐associated genes. The combination of plasma‐Seq with targeted AR analyses identified prostate cancer‐related genomic alterations in 16 of 25 (64%) treatment courses in the first cohort, in which we demonstrated that AR amplification does not always correlate with poor abiraterone and enzalutamide therapy outcome. As we observed a wide variability of ctDNA levels, we evaluated ctDNA levels and their association with clinical parameters and included the second, larger cohort for these analyses. Employing altogether 428 longitudinal plasma samples from 148 patients, we identified the presence of bone metastases, increased lactate dehydrogenase and prostate‐specific antigen (PSA) as having the strongest association with high ctDNA levels. In summary, ctDNA alterations are observable in the majority of patients with mCRPC and may eventually be useful to guide clinical decision‐making in this setting.
prostate cancer, liquid biopsies, circulating tumor DNA, androgen receptor, targeted therapies
Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide
Jelena Belic, 1 Ricarda Graf, 1 Thomas Bauernhofer, 2 Yauheniya Cherkas, 3 Peter Ulz, 1 Julie Waldispuehl‐Geigl, 1 Samantha Perakis, 1 Michael Gormley, 3 Jaymala Patel, 3 Weimin Li, 3 Jochen B. Geigl, 1 Denis Smirnov, 3 Ellen Heitzer, 1 Mitchell Gross,corresponding author 4 , † and Michael R. Speichercorresponding author 1 , †
2018 Sep 1;
Exosomes are lipid bilayer-enclosed extracellular vesicles (EVs) that contain proteins and nucleic acids. They are secreted by all cells and circulate in the blood. Specific detection and isolation of cancer cell-derived exosomes in circulation is currently lacking. Using mass spectrometry analyses, we identified a cell surface proteoglycan, glypican-1 (GPC1), specifically enriched on cancer cell-derived exosomes. GPC1+ circulating exosomes (crExos) were monitored and isolated using flow cytometry from the serum of cancer patients and mice with cancer. GPC1+ crExos were detected in the serum of patients with pancreas cancer with absolute specificity and sensitivity, distinguishing healthy subjects and patients with a benign pancreas disease from patients with early and late stage pancreas cancer. Levels of GPC1+ crExos correlate with tumor burden and survival in patients pre- and post-surgical tumor resection. GPC1+ crExos from patients and from mice with spontaneous pancreas tumors driven by oncogenic KRAS contained RNA with specific KRAS mutation, and it emerges as a reliable biomarker for the detection of PanIN lesions despite negative signal by MRI in mice. GPC1+ crExos may serve as a potential non-invasive diagnostic and screening tool to detect early stages of pancreas cancer to facilitate possible curative surgical therapy.
Glypican1 identifies cancer exosomes and facilitates early detection of cancer
Sonia A. Melo,1,#* Linda B. Luecke,1,* Christoph Kahlert,1,* Agustin F. Fernandez,2 Seth T. Gammon,3 Judith Kaye,1 Valerie S. LeBleu,1 Elizabeth A. Mittendorf,4 Juergen Weitz,5 Nuh Rahbari,5 Christoph Reissfelder,5 Christian Pilarsky,5 Mario F. Fraga,2,6 David Piwnica-Worms,3 and Raghu Kalluri1,§
2016 Jul 9.
In the molecule of the title compound, C15H13Cl2N3O2, the triazole ring is oriented at dihedral angles of 2.54 (13) and 44.43 (12)°, respectively with respect to the furan and dichlorobenzene rings. The dihedral angle between the dichlorobenzene and furan rings is 46.75 (12)°. In the crystal structure, intermolecular C—H⋯O hydrogen bonds link the molecules into centrosymmetric dimers and π-π contacts between dichlorobenzene rings [centroid-centroid distance = 3.583 (2) a] may further stabilize the structure. Intermolecular C—H⋯π contacts between the triazole and furan rings also occur.
ozden ozel Guven,a Hakan Tahtacı,a Simon J. Coles,b and Tuncer Hokelekc,*
2010 Jan 1;